Boosting cancer therapy by targeting TREM2
Targeting TREM2 to boost anti-cancer therapy
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-10910908
This study is looking at how blocking a specific immune receptor called TREM2 might make cancer treatments work better, especially for those using immune checkpoint therapy, and it could help develop more effective options for patients in the future.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10910908 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting the TREM2 immune receptor can enhance the effectiveness of cancer treatments, particularly immune checkpoint therapy. By studying mouse models, the researchers aim to understand how blocking TREM2 can alter the tumor microenvironment and improve immune responses against tumors. The approach involves using antibodies to inhibit TREM2 and observing the resulting changes in tumor growth and immune cell behavior. Patients may benefit from insights that could lead to more effective cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancer that have shown resistance to current immune therapies.
Not a fit: Patients with cancers that are already effectively treated by existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment options that are more effective for patients with certain tumors.
How similar studies have performed: Other research has shown promising results in enhancing cancer therapies by manipulating immune receptors, suggesting potential for success in this approach.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COLONNA, MARCO — WASHINGTON UNIVERSITY
- Study coordinator: COLONNA, MARCO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Alzheimer's disease model